LNTH
NASDAQLantheus Holdings Inc.
Price$100.89-0.36 (-0.36%)
01:30 PM07:45 PM
News · 26 weeks58+650%
2026-03-012026-08-23
Mix2490d
- SEC Filings9(38%)
- Other7(29%)
- Insider4(17%)
- Earnings3(13%)
- Leadership1(4%)
Latest news
25 items- INSIDERChief Accounting Officer Brown Kimberly covered exercise/tax liability with 463 shares, decreasing direct ownership by 3% to 13,263 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDEROfficer Dinkelborg Ludger covered exercise/tax liability with 2,536 shares, decreasing direct ownership by 7% to 33,195 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- PRLantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s DiseaseBEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle (NFT) pathology. TAUKLARIFY has a limitation of use. The safety a
- SECSEC Form DEFA14A filed by Lantheus Holdings Inc.DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
- SECSEC Form 10-Q filed by Lantheus Holdings Inc.10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECLantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRLantheus Reports Second Quarter 2026 Financial ResultsWorldwide revenue of $388.2 million in the second quarter of 2026GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company
- SECSEC Form DEFA14A filed by Lantheus Holdings Inc.DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECSEC Form DEFA14A filed by Lantheus Holdings Inc.DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECSEC Form 8-K filed by Lantheus Holdings Inc.8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECSEC Form DEFA14A filed by Lantheus Holdings Inc.DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECSEC Form DEFA14A filed by Lantheus Holdings Inc.DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
- SECLantheus Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRCurium Announces Definitive Agreement to Merge with LantheusStrategic transaction would bring Curium's theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business Total transaction consideration to Lantheus shareholders of up to $114.50 per share in cash for an aggregate transaction value of up to $8.0 billion – representing a premium of 38% to Lantheus’ unaffected 60-day volume-weighted average price and a premium of 29% to Lantheus’ unaffected 30-day volume-weighted average price Provides for near-term certain value for Lantheus shareholders of $102.50 per share in cash at closing and up to an additional $12.00 per share of Contingent Value Rights tied to specified performance mile
- PRLantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern TimeBEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 3
- PRRadioMedix Appoints Brian A. Markison to Board of DirectorsHOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026. "We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth," said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. "Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading radiopharmaceu
- PRLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). The FDA stated that the agency cannot approve the NDA by the Prescription Drug User Fee Act (PDUFA) action date of June 29, 2026, du
- INSIDERDirector Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- INSIDERExecutive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
- PRLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days followi
- PRLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearBEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI's Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients. "These resu
- SECSEC Form SD filed by Lantheus Holdings Inc.SD - Lantheus Holdings, Inc. (0001521036) (Filer)
- PRLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceBEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days following
- PRLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual MeetingBEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA. Presentation details are as follows: Date & Time: Monday, June 1, 2026, 10:30 am – 11:15 am PT Session Type: PosterSession Title: Oncology Clinical Diagnosis and Therapy Scientific Session Session Number: MTA06 – Screen 29Title: Impact of PSMA-PET wi
LNTH FAQ
7 questionsWhat does Lantheus Holdings Inc. do?
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for...Where does LNTH stock trade?
Lantheus Holdings Inc. (LNTH) is listed on NASDAQ.What sector and industry is LNTH in?
Lantheus Holdings Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Lantheus Holdings Inc. go public?
Lantheus Holdings Inc. (LNTH) completed its IPO in 2015.What are analysts saying about LNTH?
Lantheus Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-02-26.What companies are similar to LNTH?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.), NEOG (Neogen Corporation). Compare LNTH side-by-side with any of them on Quantisnow.How can I track LNTH on Quantisnow?
Quantisnow aggregates Lantheus Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LNTH to receive live email and push alerts on every new disclosure.